Clinical Trial Update: Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults [Phase 4]

View source ↗

Summary

A Phase 4 study comparing continuation of protease-inhibitor-based second-line therapy versus switching to B/F/TAF in virologically suppressed adults with HIV-1…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• B/F/TAF (emtricitabine/tenofovir alafenamide/cobicistat-darunavir)

Snippet

Sponsor: Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic | Conditions: HIV-1-infection, Antiretroviral Therapy | Phase 4 | Status: UNKNOWN